FDA.reportPublic FDA data

Avtozma 162 MG in 0.9 ML Prefilled Syringe

RxCUI
2705432
RxNorm name
Avtozma 162 MG in 0.9 ML Prefilled Syringe
Display name
Avtozma 162 MG in 0.9 ML Prefilled Syringe
Full name
Avtozma 162 MG in 0.9 ML Prefilled Syringe
Term type
PSN
Status
DailyMed mapping
Updated
2026-06-04 23:38:59

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
761420Avtozmatocilizumab-anoh351(k) InterchangeableRx2026-08-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
AVTOZMATOCILIZUMABCELLTRION USA, Inc.581c288f-8015-40ef-a4c3-683c96db193d2026-07-27Boxed warning, Warnings, Adverse reactionsExact identifier
rxcui: 2705432

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
581c288f-8015-40ef-a4c3-683c96db193dAvtozma 162 MG in 0.9 ML Prefilled Syringe [PSN] · 0.9 ML tocilizumab-anoh 180 MG/ML Prefilled Syringe [Avtozma] [SBD] · Avtozma 162 MG per 0.9 ML Prefilled Syringe [SY] · Avtozma 180 MG/ML per 0.9 ML Prefilled Syringe [SY]44These highlights do not include all the information needed to use AVTOZMA safely and effectively. See full prescribing information for AVTOZMA. AVTOZMA ® (tocilizumab-anoh) injection, for intravenous or subcutaneous use Initial U.S. Approval: 2025 AVTOZMA (tocilizumab-anoh) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful20260123